Pre-existing autoimmune disease as a risk factor for immune-related adverse events in cancer patients receiving immune checkpoint inhibitors
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0306995 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Hidetoshi Sumimoto und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Shiga University of Medical Science, Otsu, Shiga, Japan. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Autoimmune Diseases, Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege, Patientensicherheit
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have been widely used as standard therapies for various cancers. However, in 20–30% of cases, ICIs can lead to immune-related adverse events (irAEs), which sometimes require discontinuation of treatment. Due to the increased risk of irAEs, patients with pre-existing autoimmune diseases (AI) are often advised against receiving ICIs. However, there has not been sufficient objective risk assessment for AI. In our study, we conducted logistic regression analysis to assess the risk of irAEs by analyzing 478 cases that received anti-PD-(L)1 Ab and/or anti-CTLA4 Ab at our hospital between April 3, 2017, and May 24, 2022. Among these cases, 28 (5.9%) had pre-existing AI. We selected several independent factors for analysis: gender, age, performance status (PS), cancer type, type of ICI, type of combined anti-cancer agents, best overall response, and pre-existing AI. The adjusted odds ratio (OR) of AI for irAE occurrence was 2.52 [95% CI: 1.08–5.86] (p = 0.033), and the adjusted OR of AI for ICI discontinuation due to irAE was 3.32 [1.41–7.78] (p = 0.006). Patients with pre-existing AI experienced a significantly shorter irAE-free survival time compared to those without AI (median irAE-free survival: 5.7 months [95% CI: 3.5–7.8] vs 10.4 months [95% CI: 7.9–12.9], respectively, p = 0.035). Frequently observed irAEs in full ICI cohort, such as dermatologic issues (7.5%), pneumonitis (7.1%), hepatitis (4.6%), and hypothyroidism (4.2%), were often accompanied by pre-existing AI. Furthermore, pre-existing AI flared up in 6 cases (37.5% in AI-positive irAE-positive cases). The activity of AI was not related to the occurrence of irAEs. Grade 3 or higher irAEs were observed in 6 out of 20 (30.0%) cases in AI-accompanied patients complicated with irAEs. Although having a complicated AI increases the risk of irAEs, it may not necessarily be a contraindication for ICI treatment if closely monitored. (292
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Shiga University of Medical Science, Otsu, Shiga, Japan.
- Cancer Center, Shiga University of Medical Science, Otsu, Shiga, Japan.
- Center for Advanced Medicine Against Cancer, Shiga University of Medical Science, Otsu, Shiga, Japan.
- Department of Pharmacy, Shiga University of Medical Science Hospital, Otsu, Shiga, Japan.
- Nursing Department, Shiga University of Medical Science Hospital, Otsu, Shiga, Japan.
- Center for Antibody and Vaccine Therapy, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Yataro Daigo
Zitieren
APA
Sumimoto, H., Noda, S., Koide, H., Douke, Y., Sakai, K., Nishikawa, A., Tomioka, A., Hori, M., Nakato, H., Kimura, Y., Tokuda, A., Takano, A., Teramoto, K., Murata, S., & Daigo, Y. (2024). Pre-existing autoimmune disease as a risk factor for immune-related adverse events in cancer patients receiving immune checkpoint inhibitors. PLOS ONE. https://doi.org/10.1371/journal.pone.0306995
Vancouver
Sumimoto H, Noda S, Koide H, Douke Y, Sakai K, Nishikawa A, et al. Pre-existing autoimmune disease as a risk factor for immune-related adverse events in cancer patients receiving immune checkpoint inhibitors. PLOS ONE. 2024. doi:10.1371/journal.pone.0306995
BibTeX
@article{Sumimoto2024,
author = {Sumimoto, Hidetoshi and Noda, Satoshi and Koide, Hiroyoshi and Douke, Yutaro and Sakai, Kosuke and Nishikawa, Akihito and Tomioka, Azumi and Hori, Maki and Nakato, Hiromi and Kimura, Yuri and Tokuda, Aya and Takano, Atsushi and Teramoto, Koji and Murata, Satoshi and Daigo, Yataro},
title = {Pre-existing autoimmune disease as a risk factor for immune-related adverse events in cancer patients receiving immune checkpoint inhibitors},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0306995}
}
EUVIMED